IP Library Granted Patent US 11,623,965
Granted Patent B2
US 11,623,965 · App. 16/103,654 · Granted Apr 11, 2023

Prodruggable antibodies, prodrugs thereof, and methods of use and making

Inventors: Stanley R. Krystek, Jr. (Ringoes, NJ); Yong Zhang (West Windsor, NJ); Gregory D. Vite (Titusville, NJ); Arvind Rajpal (San Francisco, CA); Chetana Rao-Naik (Walnut Creek, CA); Paul E. Morin (Pennington, NJ); Mohan Srinivasan (Cupertino, CA); Zheng Lin (North Wales, PA); Virginie Lafont (Lawrence Township, NJ); Alla Pritsker (Morganville, NJ)
Assignee: Bristol-Myers Squibb Company
C07K16/464A61K39/39533A61K47/60A61K47/65C07K16/2818C07K16/2878A61P29/00A61P35/00C07K2317/24C07K2317/515C07K2317/565C07K2317/76C07K2319/50C12Y304/21109
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,623,965
App. No.
16/103,654
Granted
Apr 11, 2023
Kind
B2
Abstract

A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Claims (18)

1. A prodrugged antibody according to formula (I)

(BM-L) m -Ab  (I)

wherein

Ab is an antibody having at least one amino acid in its heavy or light chain variable region replaced by a Cys, wherein the replaced amino acid (a) is in a framework region; (b) has a side chain exposure of at least 30% and (c) is within 10 Å, of a CDR amino acid;

BM is a blocking moiety that inhibits binding of Ab to its antigen;

each L is, independently, a linker moiety bonded to BM and Ab, L comprising a cleavable moiety and being bonded to Ab at aforesaid Cys; and

m is 1, 2, 3, or 4; and

wherein blocking moiety BM is a poly(ethylene glycol).

2. The prodrugged antibody of claim 1 , wherein the at least one replaced amino acid in antibody Ab is at Kabat position 1, 3, 5, 19, 23, 25, 43, 46, 68, 72, 74, 75, 76, 82a, 82b, 83, 84, 85, or 105 of the heavy chain variable region or at Kabat position 1, 3, 5, 7, 8, 18, 20, 45, 57, 60, 63, 65, 66, 67, 69, 77, or 100 of the light chain variable region.

3. The prodrugged antibody of claim 1 , wherein the at least one replaced amino acid in antibody Ab is at Kabat position 23 of the heavy chain or Kabat position 67 of the light chain.

4. The prodrugged antibody of claim 1 , wherein the at least one replaced amino acid in antibody Ab is at Kabat position 23 of the heavy chain.

5. The prodrugged antibody of claim 1 , wherein the at least one replaced amino acid in antibody Ab is Kabat position 67 of the light chain.

6. The prodrugged antibody of claim 1 , wherein the poly(ethylene glycol) has a molecular weight of at least about 2 kDa.

7. The prodrugged antibody of claim 1 , wherein cleavable moiety in L is an enzymatically cleavable peptide.

8. The prodrugged antibody of claim 7 , wherein the enzymatically cleavable peptide is cleavable by at least one enzyme selected from the group consisting of fibroblast activation protein (FAP), urokinase-type plasminogen activator (uPA, urokinase), MT-SP1/matriptase, legumain, and a matrix metalloprotease.

9. The prodrugged antibody of claim 8 , wherein the enzyme is matriptase.

10. The prodrugged antibody of claim 7 , wherein the enzymatically cleavable peptide is LSGRSDNH (SEQ ID NO:5), LSGX (SEQ ID NO:16) or LSGK (SEQ ID NO:16).

11. The prodrugged antibody of claim 1 , having a structure according to formula (IIa) to (IIh):

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2018
From: KRYSTEK, STANLEY R., JR.; ZHANG, YONG; VITE, GREGORY D.; RAJPAL, ARVIND; RAO-NAIK, CHETANA; MORIN, PAUL E.; SRINIVASAN, MOHAN; LIN, ZHENG; LAFONT, VIRGINIE; PRITSKER, ALLA
To: BRISTOL-MYERS SQUIBB COMPANY
Reel/Frame 047550/0760 →
Continuity (2)
Provisional Application 62546252 · Aug 16, 2017
Related Publication 20190055321A1 · Feb 21, 2019